Pandion Therapeutics, Inc.·4

Jul 21, 7:28 PM ET

Freedman Edward D. 4

4 · Pandion Therapeutics, Inc. · Filed Jul 21, 2020

Insider Transaction Report

Form 4
Period: 2020-07-17
Freedman Edward D.
Chief Operating Officer
Transactions
  • Award

    Stock Option (right to buy)

    2020-07-17+53,13153,131 total
    Exercise: $18.00Exp: 2030-07-16Common Stock (53,131 underlying)
  • Award

    Stock Option (right to buy)

    2020-07-17+660660 total
    Exercise: $18.00Exp: 2030-07-16Common Stock (660 underlying)
  • Conversion

    Series B Preferred Stock

    2020-07-2111,9740 total
    Common Stock (2,348 underlying)
  • Conversion

    Common Stock

    2020-07-21+2,34854,461 total
  • Award

    Stock Option (right to buy)

    2020-07-17+2,1122,112 total
    Exercise: $18.00Exp: 2030-07-16Common Stock (2,112 underlying)
Footnotes (4)
  • [F1]The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  • [F2]This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on October 1, 2020, with the remainder of the shares vesting in equal monthly installments following October 1, 2020 through October 1, 2023, subject to the reporting person's continued service on each applicable vesting date.
  • [F3]This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on May 29, 2021, with the remainder of the shares vesting in equal monthly installments following May 29, 2021 through May 29, 2024, subject to the reporting person's continued service on each applicable vesting date.
  • [F4]This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on May 21, 2021, with the remainder of the shares vesting in equal monthly installments following May 21, 2021 through May 21, 2024, subject to the reporting person's continued service on each applicable vesting date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION